1915-P: Targeting Remission of Type 2 Diabetes Using a Digital Education and Behavior Change Program Improves Insulin Sensitivity and Liver Fat Content in Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1915-P
Author(s):  
DOMINIK PESTA ◽  
OANA P. ZAHARIA ◽  
YULIYA KUPRIYANOVA ◽  
JONG-HEE HWANG ◽  
DANIEL F. MARKGRAF ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitivity ◽  
Behavior Change ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Digital Education ◽  
And Behavior ◽  
Behavior Change Program

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

2007 ◽  
Vol 292 (3) ◽  
pp. E829-E835 ◽  
Author(s):  
Leena Juurinen ◽  
Mirja Tiikkainen ◽  
Anna-Maija Häkkinen ◽  
Antti Hakkarainen ◽  
Hannele Yki-Järvinen
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitivity ◽  
Insulin Therapy ◽  
Fat Content ◽  
Fat Free Mass ◽  
Liver Fat ◽  
Whole Body ◽  
Liver Fat Content ◽  
Hepatic Insulin Sensitivity

We determined whether insulin therapy changes liver fat content (LFAT) or hepatic insulin sensitivity in type 2 diabetes. Fourteen patients with type 2 diabetes (age 51 ± 2 yr, body mass index 33.1 ± 1.4 kg/m2) treated with metformin alone received additional basal insulin for 7 mo. Liver fat (proton magnetic resonance spectroscopy), fat distribution (MRI), fat-free and fat mass, and whole body and hepatic insulin sensitivity (6-h euglycemic hyperinsulinemic clamp combined with infusion of [3-3H]glucose) were measured. The insulin dose averaged 75 ± 10 IU/day (0.69 ± 0.08 IU/kg, range 24–132 IU/day). Glycosylated hemoglobin A1c (Hb A1c) decreased from 8.9 ± 0.3 to 7.4 ± 0.2% ( P < 0.001). Whole body insulin sensitivity increased from 2.21 ± 0.38 to 3.08 ± 0.40 mg/kg fat-free mass (FFM)·min ( P < 0.05). This improvement could be attributed to enhanced suppression of hepatic glucose production (HGP) by insulin (HGP 1.04 ± 0.28 vs. 0.21 ± 0.19 mg/kg FFM·min, P < 0.01). The percent suppression of HGP by insulin increased from 72 ± 8 to 105 ± 11% ( P < 0.01). LFAT decreased from 17 ± 3 to 14 ± 3% ( P < 0.05). The change in LFAT was significantly correlated with that in hepatic insulin sensitivity ( r = 0.56, P < 0.05). Body weight increased by 3.0 ± 1.1 kg ( P < 0.05). Of this, 83% was due to an increase in fat-free mass ( P < 0.01). Fat distribution and serum adiponectin concentrations remained unchanged while serum free fatty acids decreased significantly. Conclusions: insulin therapy improves hepatic insulin sensitivity and slightly but significantly reduces liver fat content, independent of serum adiponectin.

Diabetes Remission Clinical Trial (DiRECT)—Plasma Liver Function Tests Reflect Change in Liver Fat Content in Early Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1834-P
Author(s):  
SVIATLANA V. ZHYZHNEUSKAYA ◽  
AHMAD AL-MRABEH ◽  
CARL PETERS ◽  
ALISON C. BARNES ◽  
KIEREN G. HOLLINGSWORTH ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Liver Function ◽  
Liver Function Tests ◽  
Fat Content ◽  
Diabetes Remission ◽  
Liver Fat ◽  
Early Type ◽  
Liver Fat Content

scholarly journals A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial

Diabetologia ◽  
2019 ◽  
Vol 62 (11) ◽  
pp. 2066-2078 ◽  
Author(s):  
Mads J. Skytte ◽  
Amirsalar Samkani ◽  
Amy D. Petersen ◽  
Mads N. Thomsen ◽  
Arne Astrup ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
High Protein Diet ◽  
Fat Content ◽  
Protein Diet ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Randomised Controlled

Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes

2006 ◽  
Vol 291 (2) ◽  
pp. E282-E290 ◽  
Author(s):  
Riikka Lautamäki ◽  
Ronald Borra ◽  
Patricia Iozzo ◽  
Markku Komu ◽  
Terho Lehtimäki ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Liver Steatosis ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Artery Disease ◽  
Myocardial Insulin Resistance ◽  
High Liver

Nonalcoholic fatty liver (NAFL) is a common comorbidity in patients with type 2 diabetes and links to the risk of coronary syndromes. The aim was to determine the manifestations of metabolic syndrome in different organs in patients with liver steatosis. We studied 55 type 2 diabetic patients with coronary artery disease using positron emission tomography. Myocardial perfusion was measured with [15O]H2O and myocardial and skeletal muscle glucose uptake with 2-deoxy-2-[18F]fluoro-d-glucose during hyperinsulinemic euglycemia. Liver fat content was determined by magnetic resonance proton spectroscopy. Patients were divided on the basis of their median (8%) into two groups with low (4.6 ± 2.0%) and high (17.4 ± 8.0%) liver fat content. The groups were well matched for age, BMI, and fasting plasma glucose. In addition to insulin resistance at the whole body level ( P = 0.012) and muscle ( P = 0.002), the high liver fat group had lower insulin-stimulated myocardial glucose uptake ( P = 0.040) and glucose extraction rate ( P = 0.0006) compared with the low liver fat group. In multiple regression analysis, liver fat content was the most significant explanatory variable for myocardial insulin resistance. In addition, the high liver fat group had increased concentrations of high sensitivity C-reactive protein, soluble forms of E-selectin, vascular adhesion protein-1, and intercellular adhesion molecule-1 ( P < 0.05) and lower coronary flow reserve ( P = 0.02) compared with the low liver fat group. In conclusion, in patients with type 2 diabetes and coronary artery disease, liver fat content is a novel independent indicator of myocardial insulin resistance and reduced coronary functional capacity. Further studies will reveal the effect of hepatic fat reduction on myocardial metabolism and coronary function.

scholarly journals Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Diabetes Care ◽  
2019 ◽  
Vol 43 (2) ◽  
pp. 298-305 ◽  
Author(s):  
Sabine Kahl ◽  
Sofiya Gancheva ◽  
Klaus Straßburger ◽  
Christian Herder ◽  
Jürgen Machann ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Controlled Trial ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Double Blind

Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes

Hepatology ◽  
2011 ◽  
Vol 54 (3) ◽  
pp. 1109-1110 ◽  
Author(s):  
Jean Michel Petit ◽  
Boris Guiu ◽  
David Masson ◽  
Jean-Pierre Cercueil ◽  
Patrick Hillon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variant ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Apolipoprotein C3

scholarly journals Liver Fat Content in Type 2 Diabetes: Relationship With Hepatic Perfusion and Substrate Metabolism

Diabetes ◽  
2010 ◽  
Vol 59 (11) ◽  
pp. 2747-2754 ◽  
Author(s):  
L. J. Rijzewijk ◽  
R. W. van der Meer ◽  
M. Lubberink ◽  
H. J. Lamb ◽  
J. A. Romijn ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Hepatic Perfusion ◽  
Substrate Metabolism
Sign in / Sign up

Export Citation Format

Share Document